Calvert's formula for dosing carboplatin: Overview and concerns of applicability in high-dose setting

被引：13

作者：

Mazumdar, M

Smith, A

Tong, WP

Motzer, RJ

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Therapeut Pharmacol, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, Div Solid Tumor Oncol, Dept Med, New York, NY 10021 USA

来源：

JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2000年 / 92卷 / 17期

关键词：

D O I：

10.1093/jnci/92.17.1434

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：1434 / 1436

页数：3

共 17 条

[1] Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer [J].

Belani, CP ;

Kearns, CM ;

Zuhowski, EG ;

Erkmen, K ;

Hiponia, D ;

Zacharski, D ;

Engstrom, C ;

Ramanathan, RK ;

Capozzoli, MJ ;

Aisner, J ;

Egorin, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :676-684

[2] CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].

CALVERT, AH ;

NEWELL, DR ;

GUMBRELL, LA ;

OREILLY, S ;

BURNELL, M ;

BOXALL, FE ;

SIDDIK, ZH ;

JUDSON, IR ;

GORE, ME ;

WILTSHAW, E .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756

[3]

Carmichael J, 1996, SEMIN ONCOL, V23, P55

[4] A PHARMACOLOGICALLY GUIDED PHASE-I STUDY OF CARBOPLATIN COMBINATION WITH METHOTREXATE AND VINBLASTINE IN ADVANCED UROTHELIAL CANCER [J].

CHATELUT, E ;

CHEVREAU, C ;

BRUNNER, V ;

MARTINEZ, M ;

HOUIN, G ;

BUGAT, R ;

CANAL, P .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (05) :391-396

[5]

FORD C, 1997, SEMIN ONCOL S17, V24

[6] Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels [J].

Ghazal-Aswad, S ;

Tilby, MJ ;

Lind, M ;

Baily, N ;

Sinha, DP ;

Calvert, AH ;

Newell, DR .

ANNALS OF ONCOLOGY, 1999, 10 (03) :329-334

[7] Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer [J].

Gore, M ;

Mainwaring, P ;

A'Hern, R ;

MacFarlane, V ;

Slevin, M ;

Harper, P ;

Osborne, R ;

Mansi, J ;

Blake, P ;

Wiltshaw, E ;

Shepherd, J .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) :2426-2434

[8] Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer [J].

Huizing, MT ;

vanWarmerdam, LJC ;

Rosing, H ;

Schaefers, MCW ;

Lai, A ;

Helmerhorst, TJM ;

Veenhof, CHN ;

Birkhofer, MJ ;

Rodenhuis, S ;

Beijnen, JH ;

tenBokkelHuinink, WW .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :1953-1964

[9] PACLITAXEL AND CARBOPLATIN IN COMBINATION IN THE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG-CANCER - A PHASE-II TOXICITY, RESPONSE, AND SURVIVAL ANALYSIS [J].

LANGER, CJ ;

LEIGHTON, JC ;

COMIS, RL ;

ODWYER, PJ ;

MCALEER, CA ;

BONJO, CA ;

ENGSTROM, PF ;

LITWIN, S ;

OZOLS, RF .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1860-1870

[10] Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients [J].

Motzer, RJ ;

Mazumdar, M ;

Sheinfeld, J ;

Bajorin, DF ;

Macapinlac, HA ;

Bains, M ;

Reich, L ;

Flombaum, C ;

Mariani, T ;

Tong, WP ;

Bosl, GJ .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (06) :1173-1180

← 1 2 →